DELEE offering is now closed and is no longer accepting investments.

Early cancer diagnosis and treatment monitoring

INVEST IN DELEE TODAY!

At Delee, we have created the CytoCatch™️ isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
DELEE

Reasons to Invest

  • Blood-based assay for the early detection of cancer and monitoring of the applied treatments’ effectiveness, which is enabled by two independent devices created to effectively isolate and analyze circulating tumor cells (CTCs). Delee has a fully functional technology that is being successfully tested for prostate and breast cancer with pre-orders worth a potential value of over $2.5 million USD. 
  • Delee is backed by Y Combinator and StartX, and has raised over $2.4 million USD in funding. In 2020, the global circulating tumor cell market was valued at $8.4 billion USD, and it is expected to reach $18.3 billion USD by 2027.
  • We have built an experienced team of specialists in the fields of molecular biology, electronics, artificial intelligence, clinical oncology, product design, and manufacture.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

Since our last raise


Milestones Reached

  • We improved the capabilities of our previous prototypes to greatly increase the robustness and reliability of our CTC blood-based assay. 
  • We completed the commercial versions of the devices that enable the CTC blood-based assay. 
  • We expanded the number of collaborations with medical institutions, which will allow us to clinically validate our technology in less time.
  • We increased the number of processed patient samples to assess the feasibility of using our technology for various cancer-related clinical applications. 
  • We expanded our team in order to accelerate the commercial launch of our technology.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

The Problem



* Source


Cancer has become a major global health issue. According to the International Agency for Research on Cancer (IARC), in 2020, the number of new registered cases surpassed 19.2 M globally, whereas over 9.9 M deaths occurred due to this disease (Source). Despite all the recent breakthroughs in cancer treatments, it is estimated that by 2040, the number of new registered cases and fatalities per year will increase to 30.2 M and 16.3 M, respectively (Source, Source). The National Cancer Institute (NCI) estimates that 39.5% of Americans will be diagnosed with cancer at some point during their lifetime (Source), unfortunately, many of these people will lose their lives because of it. One of the main reasons cancer has such a high mortality rate is due to the current lack of tests with the required sensitivity and specificity to enable an early diagnosis of the disease. 


When it comes to cancer, the detection of tumors at an early stage is key because the survival rate in most types of cancer is directly related to the stage at which tumors are detected. For example, the 5-year relative survival rate for breast cancer when detected at early stages is 99%, but drops to 28% when detected at late stages (Source). Furthermore, early detection has the potential to reduce the financial burden of health care on individuals and public health services mainly because cancer treatments used for treating localized disease are less complex, and therefore, less expensive; according to the World Health Organization (WHO), studies made in high-income countries have shown that the cost of cancer treatment, when detected at early stages, is 2 to 4 times less expensive than at advanced stages (Source). 


Moreover, there is a lack of technological resources to provide effective monitoring of the applied cancer treatments’ efficacy, which may significantly reduce the patients’ chances of survival given that the right treatment at the right time for each cancer patient may not be administered due to the lack of information available for physicians. 


Since there is an unmet need for tests that can reliably detect cancer at early stages and monitor the applied treatments’ effectiveness, the research community has been actively searching for novel biomarkers that can provide clinical information for these purposes. The isolation of circulating tumor cells (CTCs) from blood is a recent alternative that could address this need. In the last decade, CTCs have attracted a significant amount of attention for their potential use as a blood-based biomarker for a broad range of cancer-related clinical applications. CTCs are malignant cells that are shed from the primary and/or metastatic solid tumors that infiltrate into the vascular and lymphatic systems; these cells play a fundamental role in the metastatic process of non-hematological cancers (Source, Source).



Technologies that detect and isolate CTCs from blood can be used to develop assays that could enable early cancer detection and monitor the applied treatments’ effectiveness. However, the isolation of these malignant cells from blood represents a major technological challenge due to their heterogeneity and extremely low numbers in comparison to blood cells (Source, Source); on average, you can find around 40.5 billion cells in 7.5 mL of blood, while a cancer patient may have between 1 and 1000 CTCs in the same volume (Source).

Even though there currently exists multiple cell sorting methods, such as fluorescent-activated cell sorting, magnetic-activated cell sorting, fluorescent-activated droplet sorting, and density gradient centrifugation, these are not compatible with whole blood samples and/or do not have the sufficient sensitivity and specificity to correctly isolate CTCs from blood, which have prevented the development of assays with potential clinical utility... until now.

Our Solution


At Delee, we have created the CytoCatch™  isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

How it works



For the assay, a single blood tube is extracted by conventional venipuncture (the collection method that is usually used for laboratory testing). The blood sample along with several reagents are loaded on the CytoCatch™  isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The unit has an outstanding performance, it has recovery rates above 94% when processing 7.5 mL blood samples spiked with tumor cells from prostate, breast, and colorectal cancer cell lines, meaning that the platform recovers at least 94 out of 100 tumor cells spiked into the sample (Source).


Once captured, the CytoCatch™  isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis with the CytoCatch™ imaging system, which possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human error and cell loss due to manual steps.


Furthermore, the collected cells are compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs. Finally, the treating physician will get a report with the corresponding results.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

ONCOLOGICAL CLINICAL APPLICATIONS



Our technology has the specificity and sensibility required to successfully isolate and analyze CTCs from blood, which may enable the following clinical applications:


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

BENEFITS OF OUR TECHNOLOGY



The early detection of cancer and the monitoring of the applied treatments’ effectiveness will be translated into invaluable benefits for patients and their families, being the most important, and the main reason for all our work, to greatly increase their chances of defeating cancer. Furthermore, monitoring the treatments’ effectiveness could also significantly increase the odds of defeating cancer by applying the most effective treatment for each patient throughout the course of the disease, while reducing the incurred costs and the negative side effects caused by drugs that wouldn’t be effective for a particular patient.


FOR WHAT TYPES OF CANCER?



Our technology can be used for a wide variety of cancer types. There is scientific evidence that indicates the feasibility of developing CTC assays to enable clinical applications in various types of cancer, including prostate, breast, colorectal, lung, cervical, skin, and ovarian cancer, just to name a few. Prostate, breast, colorectal, and lung cancer are responsible for over 40% of new cancer cases and a third of the deaths registered worldwide due to this disease (Source). 



Traction


Pre-orders worth a potential value of over $2.5 million USD

We’ve gotten great traction since the pre-commercial launch of our technology. To date, pre-orders worth a potential value of over $2.5 million USD have been secured from research centers of various hospitals in order to use our technology as an in vitro diagnostic platform for research use only, prior to FDA clearance.

Customers


Who buys it?

Prior to acquiring FDA clearance, Delee aims to commercialize the CytoCatch™ isolation platform and imaging system as research tools, being pharmaceutical companies and research centers our main customers. Once our technology obtains FDA clearance, it will be commercialized as an in vitro diagnostic medical device for hospitals and laboratories.


Business Model


Recurring revenue through consumable and reagent sales

Prior to FDA clearance, our devices will be commercialized as research tools, where the razor and blades business model will be followed, obtaining recurrent revenue by selling the necessary reagents and consumables to perform each test. This model will be maintained once FDA gives clearance for our technology to be commercialized as an in vitro diagnostic medical device for hospitals and laboratories.


*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.


Market


An $18.3 billion USD market by 2027

According to a recent report published by Grand View Research, in 2020, the global circulating tumor cell market was valued at $8.4 billion USD, and it’s expected to reach an $18.3 billion USD valuation by 2027 (Source, Source). This growth is mainly driven by the increase in the number of cancer cases that will occur in the coming years.  



At Delee, we are initially validating our technology for prostate and breast cancer, to later expand it to lung and colorectal cancer, mainly because, in 2020 alone, these four types of cancer account for over 40% of the new cancer cases registered worldwide and were responsible for over 3.7 million deaths (Source).

Competitors


A more effective way to capture and analyze CTCs

Most of the blood tests employed as auxiliaries in the diagnosis of cancer and monitoring of the applied treatments’ effectiveness measure protein tumor markers levels, such as PSA, CA-125, and AFP. However, there are only a few protein tumor markers that are associated with a particular cancer and are clinically useful; most types of cancer have not been linked to an increase in the levels of a particular protein tumor marker (Source). Furthermore, these types of tests have a poor sensitivity and specificity, meaning that these markers may be elevated in people that do not have cancer and that not every person with a particular type of cancer will have an elevated level of the corresponding tumor marker (Source). Taking the PSA test as an example, which measures the amount of PSA in blood and is used to screen for prostate cancer, approximately 66% of men with increased levels of PSA do not have prostate cancer, whereas over 15% of the men with normal levels of PSA may have prostate cancer (Source).      


The isolation and analysis of CTCs is a relatively new practice, and physicians are starting to recognize all its potential benefits. Most of the current CTCs technologies, including the CellSearch® System, which is considered the gold standard, rely on the existence of specific proteins on the tumor cell membrane in order to capture them. However, CTCs are incredibly heterogeneous; when entering the bloodstream, they undergo a biological process that downregulates these proteins, limiting the efficiency with which these cells are captured and thereby losing valuable information (Source, Source). Our technology changes the norm by isolating CTCs irrespective of the proteins expressed in their membranes, allowing us to capture tumor cells that other technologies simply can’t.



*Images used in this photo are in the prototype phase, CytoCatch is not currently available on the market.

Our Vision



Font Size
Drop image
(or click)

Uploading

Insert Image
Drop image
(or click)

Uploading

Insert Image
Drop image
(or click)

Loading image

Quick Insert
Drop image
(or click)

Loading image

Edit Link

ABOUT

HEADQUARTERS
1211 San Dario Ave #2068
Laredo, TX 78040
VALUATION
$22.04M
PREVIOUSLY CROWDFUNDED
$1M

At Delee, we have created the CytoCatch™️ isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.

TEAM

Liza Velarde
Liza Velarde
Co Founder, Director & CEO

Liza Velarde is a co-founder and acting CEO of Delee Corp. She is a Y Combinator alumna and has a bachelor’s degree in International Business from Tecnológico de Monterrey. Velarde is responsible for the development and execution of the company's strategic plans, leading along with her co-founders, the engineering team that built Delee’s core technology. She has raised over $2.4M USD through investments, government funds, and multiple awards, and also secured pre-orders worth a potential value of over $2.5M USD. Velarde has also established strong relations with top hospitals and research centers and her work has been highly regarded by international institutions, such as Cartier Women's Initiative Awards and WeXchange (an initiative of the Inter-American Development Bank). In recent years, she has been acknowledged as one of the 50 most relevant people transforming Mexico and one of Forbes’s 100 most influential women in Mexico, and has been invited as a speaker on various international panels about cancer and entrepreneurship, such as WeXchange 2019 and The Economist: War on Cancer LATAM 2019.

Alejandro Abarca
Alejandro Abarca
Co Founder, Director & CTO

Alejandro Abarca is a co-founder and acting CTO at Delee Corp. He is a physicist, a Y Combinator, a Singularity University, and a Royal Academy of Engineering LIF alumnus. Abarca is a co-creator of the CytoCatch™ isolation platform and imaging system, which isolates and analyzes circulating tumor cells from blood samples. He has published four scientific papers in international journals. He has over ten years of experience developing and producing medical devices and biosensors, including, a microfluidic device for the isolation of rare cell subpopulations based on dielectrophoretic separation, manufacturing methods for embedding metal electrodes onto thermoplastics for microfluidic applications, and an automated imaging system to study cell’s properties by immunostaining. Abarca also has collaborated in projects related to bioprinting and point-of-care applications with various research groups at Tecnológico de Monterrey. His areas of expertise include microfabrication, manufacturing techniques for mass production, optics, and cell separation based on physical properties.

Juan Felipe Yee
Juan Felipe Yee
Co Founder, Director & CMO

Juan Felipe Yee is a co-founder and acting CMO at Delee Corp. He is a Y Combinator alumnus, and obtained a M.Sc. in Electronic Engineering and a B.Sc. in Biomedical Engineering both from Tecnológico de Monterrey. Yee is a co-creator of the CytoCatch™ isolation platform and imaging system, which isolates and analyzes circulating tumor cells from blood samples, and is responsible for planning, developing, implementing, and monitoring the overall strategy for the analytical and clinical validation of the CytoCatch™ technology. He has published 7 scientific papers in international journals and spent over a decade working and collaborating in the development of several medical devices and biosensors, including, a high intensity phototherapy LED source to treat hyperbilirubinemia in newborns, substrates made from carbon nanofiber mats coated with gold nanoparticles for the detection of specific molecules in simple solutions by SERS spectroscopy, and microfluidic devices for cell isolation based on antigen-antibody interactions, inertial forces, and dielectrophoresis.

Joost Leeflang

Joost Leeflang

Director

Joost Leeflang has over 20 years of experience in successfully driving top and bottom line growth for consumer and professional business across multiple geographies. He served as Senior VP and Global Head of Commerce responsible for Global Sales and Marketing for the Medical Imaging Business of Philips Healthcare. Prior to that, Joost occupied several key positions in the Philips Organization, including Senior VP and CEO of Philips Electronics Central and Eastern Europe, Senior VP and General Manager of Philips Lightning in Europe, Senior VP, CEO and General Manager of Philips Electronics RUC in the Healthcare & Consumer Lifestyle area, amongst others. He was the COCIR President, the European Trade Association representing the medical imaging, health ICT, and electromedical industries. Joost completed an Executive Program in Strategy and Organization at the Stanford Business School and a Master in Business Economics at the University of Groningen.

Joost Leeflang's primary occupation is being a Facilitator and Board Member of the Foundation for Natural Leadership. He serves as a part-time Director for Delee Corp., working 3 hours per week.

Chiu Chau

Chiu Chau

Engineering Advisory Board

Chau has over 20 years of experience working in the biotech industry. He is the co-founder and CTO of Opentrons, a company that commercializes open-source robots that automate dozens of key laboratory processes, also serving as its CEO for 4 years. Chau was also the VP Eng of BioArray Solutions, which was bought by Immucor in 2008, where he led the engineering team that built the core multiplex qPCR automation technology now used in most blood banks for advanced blood typing. He has been granted more than 15 US and international patents and holds a M.Sc. in Applied Physics from the Georgia Institute of Technology and a B.Sc. in Mechanical Engineering from the University of Hong Kong.

Mario Moisés Álvarez, Ph.D.

Mario Moisés Álvarez, Ph.D.

Scientific Advisory Board

Mario Moisés Álvarez is a Principal Investigator of the Alvarez-Trujillo Laboratory and the Director of the Biomedical Engineering Group at Tecnológico de Monterrey. Alvarez has been a Visiting Professor at the Harvard-MIT Health Sciences and Technology at BWH, Harvard Medical School, and a Visiting Professor at the Microsystems Technology Laboratories (MTL) at the Massachusetts Institute of Technology. His research interest is focused on the integration of bio-, micro-, and nanotechnologies into tissue, biomedical, and biopharmaceutical engineering applications. His current academic production is mainly focused on bioprinting, biomaterial and tissue engineering, development of organ-on-chip systems, point of care diagnostics, and biopharmaceutical engineering. Professor Álvarez completed an industrial postdoctoral stay at the Institute of Pharmaceutical Technology at Bristol-Myers Squibb Company, USA. He holds a Ph.D. in Chemical and Biochemical Engineering from Rutgers University, a M.Sc. in Chemical and Biochemical Engineering from Rutgers University, a M.Sc. in Chemical Engineering from Tecnológico de Monterrey, and a B.Sc. in Biochemical Engineering from Tecnológico de Monterrey. Alvarez has published over 100+ papers in international journals. He has been granted three US patents and twelve Mexican patents. Álvarez is a permanent member of the Mexican Academy of Sciences and a member of the National Research System, where he has been awarded with the highest ranking for Mexican researchers (SNI Level III)

David Mohler, M.D.

David Mohler, M.D.

Medical Advisory Board

David Mohler is an Orthopedic Surgical Oncologist, Clinical Professor, and Chief of the Musculoskeletal Tumor Service Department of Orthopedic Surgery and Sports Medicine from Stanford University Medical Center. Mohler received his B.Sc. from Stanford University and his M.D. from Cornell University Medical College. He completed an internship in General Surgery at UCLA, a residency in orthopedic surgery at the Hospital for Special Surgery, and a Metabolic Bone Disease/Bone Tumor fellowship at the Memorial Sloan-Kettering Cancer Center. With over three decades of experience in the field, he has authored and co-authored over 35 papers in peer-reviewed journals, 5 book chapters, and collaborated in various research projects. Mohler is currently a member of several prestigious associations such as the Orthopedic Research Society, the American Academy of Orthopedic Surgeons, and the Musculoskeletal Tumor Society, among others. He has an American Board of Orthopedic Surgery certification and has been honored with awards like the Alpha Omega Alpha, The National Research Service Award and the Saul Halpern, M.D. Orthopedic Educator Award.

Avatar Image

Grissel Trujillo de Santiago, Ph.D.

Grissel Trujillo de Santiago, Ph.D.

Scientific Advisory Board

Grissel Trujillo de Santiago is a Principal Investigator of the Alvarez-Trujillo Laboratory at the School of Engineering and Sciences at Tecnológico de Monterrey. She was trained as a Chemistry & Pharmacy Biologist at Universidad Autónoma de Nuevo León; she obtained her M.Sc. and Ph.D. degrees in Biotechnology from Tecnológico de Monterrey. Dr. Trujillo de Santiago conducted research in Material Sciences at the Università degli Studi di Napoli Federico II during her Ph.D. program. She was a Postdoctoral Research Fellow at Dr. Khademhosseini’s Lab in the Harvard-MIT Health Sciences and Technology Division for 2 years and at MIT’s Microsystems Technology Laboratories. She has published 45+ papers in indexed international journals and one book chapter, has been awarded with a Mexican patent, and has more than 40 participations in international conferences. She was a recipient of the For Women in Science Award from the L’Oreal-UNESCO-CONACyT-AMC foundation in 2019, and recognized as a “Distinguished citizen” by her native town in 2018. Her main area of interest and expertise is the design of biomaterials and biofabrication technologies for Tissue Engineering applications. Dr. Trujillo de Santiago research is currently focused in the development of novel platform-technologies based in chaos to produce multilayered complex 3D micro-structured living tissues.

Lauro S. Gómez, M.D., Ph.D.

Lauro S. Gómez, M.D., Ph.D.

Medical Advisory Board

Lauro S. Gómez is a Urologist and Research Director of the Department of Urology at the University Hospital “Dr. José Eleuterio González”. He has over 30 years of experience in the oncological, pediatric and male infertility fields, has authored and co-authored over 60 papers in peer-reviewed journals, and is a reviewer of various specialized medical journals. He is President of the School of Urologists of Nuevo León, a permanent member of the Mexican Academy of Surgery and the Mexican Society of Urology, and a member of the National Research System. Lauro completed his M.D. and specialty in urology at the Universidad Autónoma de Nuevo León, and received his subspecialty in pediatric urology, andrology and microsurgery from the Puigvert e Institut Dexeus Foundation of the Autonomous University of Barcelona and Necker Hospital of the Paris University.

Avatar Image

Everardo González, Ph.D.

Everardo González, Ph.D.

Biotechnology Research Scientist

Rolando Delgado, Ph.D.

Rolando Delgado, Ph.D.

Biochemical Research Scientist

Brenda Soto

Brenda Soto

Cell Biology Research Scientist

Diana Aráiz

Diana Aráiz

Molecular Biology Research Scientist

Fernanda Jasso

Fernanda Jasso

Biomedical Engineer

Gladys Díaz

Gladys Díaz

Biomedical Engineer

Miguel Esparza, Ph.D.

Miguel Esparza, Ph.D.

Electronics Research Scientist

Carlos Aguilar, Ph.D.

Carlos Aguilar, Ph.D.

Artificial Intelligence Research Scientist

Franco Chacón

Franco Chacón

Software Design Engineer

José Yee

José Yee

Software Design Engineer

Jorge Zamora

Jorge Zamora

Hardware Design Engineer

Marisol Abarca

Marisol Abarca

Mechanical Design Engineer

Mauricio González

Mauricio González

Biomedical Engineer

Ricardo García

Ricardo García

Hardware Design Engineer

Karen Velarde

Karen Velarde

Marketing & Strategic Specialist

Alitzel Trueba

Alitzel Trueba

Product Designer

Gracié Rodríguez

Gracié Rodríguez

Strategic Planning Executive

Ricardo Paredes

Ricardo Paredes

Audiovisual Producer

TERMS

DELEE
Overview
PRICE PER SHARE
$1.66
DEADLINE
Apr 7, 2022
VALUATION
$22.04M
AMOUNT RAISED
$347,497.93
Breakdown
MIN INVESTMENT
$199.20
MAX INVESTMENT
$106,998.62
MIN NUMBER OF SHARES OFFERED
6,024
OFFERING TYPE
Equity
ASSET TYPE
PREFERRED
SHARES OFFERED
Series Seed V Preferred Stock
MAX NUMBER OF SHARES OFFERED
3,012,047

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

DELEE CORP.

Corporate Address

:

1211 San Dario Ave #2068, Laredo, TX 78040

Offering Minimum

:

$9,999.84

Offering Maximum

:

$4,999,998.02

Minimum Investment Amount

(per investor)

:

$199.20











Terms


Offering Type

:

Equity

Security Name

:

Series Seed V Preferred Stock

Minimum Number of Shares Offered

:

6,024

Maximum Number of Shares Offered

:

3,012,047

Price per Share

:

$1.66

Pre-Money Valuation

:

$22,040,057.38











*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.

Investment Incentives*

Early Bird Bonus

Friends and Family - First 72 hours | 10% bonus shares

Super Early Bird - Next 7 days | 8% bonus shares

Early Bird Bonus - Next 10 days | 6% bonus shares

Volume-Based Bonus

$5,000 - 10% bonus shares

$10,000 - 12% bonus shares

$15,000 - 14% bonus shares

$20,000 - 16% bonus shares

$25,000 - 18% bonus shares

$30,000 - 20% bonus shares

*All perks occur when offering is complete.

The 10% StartEngine Owners' Bonus

Delee Corp. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series Seed V Preferred Stock at $1.66 / share, you will receive 10 additional shares, meaning you'll own 110 shares for $166. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

Example - The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.

ALL UPDATES

04.07.22

The final 6 hours to become an investor in Delee!

The campaign is 6 hours away from finishing. Thank you for your support and your feedback during our SE campaign.


If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙



04.06.22

The final 12 hours to become an investor in Delee!

The campaign is 12 hours away from finishing. Thank you for your support and your feedback during our SE campaign.


If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙


04.06.22

The final 24 hours to become an investor in Delee!

The campaign is less than 24 hours away from finishing. Thank you for your support and your feedback during our SE campaign.


If you reserved during the TTW stage this is your last chance to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙


04.05.22

Only a day left to become an investor in Delee!

We’re close to the end of our campaign. From everyone working at Delee we would like to say that your support has been very important to all of us.

If you reserved during the TTW stage there is still time to confirm your investment to get your bonus share, and to all the people interested in investing, here are some of the reasons why we think you should.


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to all investors for believing in our vision and for making it a reality.


Delee Team 💙


04.04.22

Meet the CytoCatch™ isolation platform, a powerful device for CTC isolation

Hello everyone!

Circulating tumor cells (CTCs) have attracted a significant amount of attention for their potential use as a blood-based biomarker to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment. The analysis of these cells will enable the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling. However, their heterogeneity and extremely low concentration in comparison to the other cellular components of blood, about 1–10 CTCs per billion blood cells, makes their capture extremely challenging… until now.

We have developed the CytoCatch™ isolation platform, which automatically performs the necessary steps to prepare and process the sample, capturing the contained CTCs. The CytoCatch™ isolation platform has the sensitivity to isolate a single CTC from a background of 50 billion blood cells, isolating these malignant cells by leveraging the difference in size and deformability between CTCs and blood cells. Once captured, the CytoCatch™ isolation platform executes an automated protocol to stain the collected cells with fluorescent antibodies for their further analysis, allowing the identification of the patient’s tumor biological characteristics. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human error and cell loss due to manual steps. Furthermore, the CytoCatch™ isolation platform is  compatible with traditional molecular biology techniques and next generation sequencing technologies, enabling the performance of molecular analyses to assess the genetic characteristics of the captured CTCs.



We are so excited because we are only a few months away from being able to start commercializing our technology as a research use only device, for its use in research centers and pharma companies.

We want to take this opportunity to remind you that there are less than 48 hours left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙

04.03.22

3 days left to invest in Delee!

We’re almost reaching the end of our campaign. It has been heartwarming to know that many people believe in what we’re doing and most importantly that they believe in us.


For the people that reserved but did not confirm their investment remember that you still have this period of time to confirm and receive your bonus shares.


For our followers still on the fence about investing here is why we think you should invest in us


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙


04.02.22

4 days left to invest in Delee!

We’re almost reaching the end of our campaign. It has been heartwarming to know that many people believe in what we’re doing and most importantly that they believe in us.


For the people that reserved but did not confirm their investment remember that you still have this period of time to confirm and receive your bonus shares.


For our followers still on the fence about investing here is why we think you should invest in us


  • CTCs are a very powerful biomarker; their analysis enables the study of cancer cells derived from tumors in a non-invasive way, allowing DNA, RNA, and protein-based molecular profiling, which will generate valuable information to help physicians make information-driven decisions concerning cancer diagnosis and treatment’s response assessment.

  • Delee is backed by Y Combinator, StartX, and Emles Venture Partners. 

  • The founders have a scientific background and more than 10 years of experience developing scientific instrumentation. 

  • Our company has a multidisciplinary team of scientists and engineers, and has a strong advisory board composed of people with experience in the scientific and clinical fields,

  • Delee will start commercializing its technology as a research use only device by Q4 of this year, for which FDA clearance is not required. 

  • To date, pre-orders worth a potential value of over $2.5M have been secured from 11 research centers of various hospitals, including the Stanford University Medical Center. 

  • The TAM for the use of CTCs in clinical applications is calculated at over $543B. 

  • We are running a clinical study to validate the use of our technology in applications related to prostate cancer. Furthermore, we have three patent pending applications that protect different aspects of our technology, and published peer-reviewed articles in Nature Scientific Reports.


Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙


04.01.22

Meet the CytoCatch™ imaging system, a powerful platform for CTC analysis

Hello everyone!

As you know, our technology is composed of two devices, the CytoCatch™ isolation platform, which processes the sample capturing the contained CTCs, and the CytoCatch™ imaging system, which performs the analysis of the captured cells. In this update we want to talk about some of the characteristics that make the CytoCatch™ imaging system an ideal platform for CTC analysis.

Once the sample has been processed, the substrate where the CTCs are captured is placed in the CytoCatch™ imaging system to enumerate CTCs and identify specific biological characteristics that give information to physicians about treatment selection and therapy response assessment. The CytoCatch™ imaging system has very unique characteristics that allow the complete mapping of the substrate area where the CTCs were captured, as shown in the video. This mapping is performed at different focal planes to ensure that all the cells are in focus, increasing the reliability of the analysis. Furthermore, the CytoCatch™ imaging system allows the fluorescence-based identification of up to 6 different markers in the captured cells, which gives the flexibility to create specific panels for a wide variety of cancers, providing valuable information to physicians regarding the identification of possible markers that serve as targets for targeted therapies. Finally, the CytoCatch™ imaging system has a powerful built-in AI that enumerates the captured CTCs and categorizes them based on their biological characteristics, thereby eliminating the subjective interpretation of operators and increasing the reproducibility of analysis, while decreasing the time needed to manually enumerate the CTCs captured.



We are so excited because we are only a few months away from being able to start commercializing our technology as a research use only device, for its use in research centers and pharma companies.

We want to take this opportunity to remind you that there are only 5 days left until Delee’s campaign ends. For those who reserved shares during the TTW stage, you only have this period of time to confirm your investment and receive your 10% bonus shares. If you haven't made an investment yet, and you’re interested, there’s still time to do so.

Thanks to everyone who supported us by becoming investors in Delee.


Delee Team 💙

04.01.22

Delee passes $300,000 in investments!

We are thrilled to announce that our campaign has passed $300k in investments, we are so happy to reach another milestone!

What we have accomplished has only been possible thanks to everyone who has joined our mission of revolutionizing cancer blood tests.

We are on the final days of our campaign, for those who reserved shares during the TTW stage, these are the last days you have to confirm your investment and receive your 10% bonus shares.

And if you haven't invested yet, you still have time to do so.


Delee Team 💙



03.31.22

1 week left to invest in Delee!

Hello everyone!

The final week of our campaign has started. To everyone that has supported us and has become an investor we would like to thank you for allowing us to continue our endeavor of helping people with cancer detection and treatment.

For those who reserved shares during the TTW stage, you still have this next week to confirm your investment and receive your 10% bonus shares.

And if you haven't invested yet, and you’re interested, you still have time to do so.

Thank you!


Delee Team 💙












REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into DELEE.

$199.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$5,000.00

First Tier

$5,000 - 10% bonus shares

$10,000.00

Second Tier

$10,000 - 12% bonus shares

$15,000.00

Third Tier

$15,000 - 14% bonus shares

$20,000.00

Fourth Tier

$20,000 - 16% bonus shares

$25,000.00

Fifth Tier

$25,000 - 18% bonus shares

$30,000.00

Sixth Tier

$30,000 - 20% bonus shares

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.